UK MHRA: Your Compass for Global AI Health Investment Trends

Listen to this article · 8 min listen

The field of AI health regulation is a dynamic one, where national bodies often signal broader international trends. For policy analysts tracking these shifts, observing a single influential regulator can offer important insights into the direction of larger, multi-national frameworks. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) provides just such a lens, offering a distinct voice within the ongoing global conversation on AI medical device oversight.

The Value of a National Regulatory Compass

In an increasingly interconnected regulatory environment, the temptation exists to focus solely on the largest blocs, such as the European Union or the United States. However, this approach risks overlooking the granular detail and specific interpretations that national regulators provide. The MHRA, while operating within its own sovereign jurisdiction, frequently engages with and influences international standards, making its positions a valuable bellwether. Its guidance often reflects a pragmatic approach to innovation while maintaining a clear focus on patient safety, a balance that many other regulatory bodies also seek to strike. Understanding the MHRA’s stance on specific AI health tools can illuminate areas of convergence and divergence with frameworks like the EU Medical Device Regulation (MDR), offering a nuanced view of the global regulatory trajectory.

Working through Overlap and Divergence with EU MDR

The UK’s post-Brexit regulatory field has allowed the MHRA to chart a course that, while often aligned with the principles of EU MDR, also exhibits distinct characteristics. Both frameworks emphasize strong clinical evidence, complete quality management systems (QMS), and post-market surveillance for AI-powered medical devices. For instance, the core tenets of Good Machine Learning Practice (GMLP), which advocate for transparency, data quality, and continuous monitoring of AI performance, find resonance in both UK and EU guidance. MHRA guidance on AI as a medical device However, the divergence often lies in the specifics of implementation and interpretation. The EU Medical Device Regulation (MDR), now complemented by the EU AI Act which entered into force on August 1, 2024, presents a highly prescriptive pathway, known for its stringent conformity assessment procedures and the central role of Notified Bodies. The AI Act classifies most AI-enabled medical products as ‘high-risk,’ introducing a dual compliance framework that complements existing regulations. The MHRA, while maintaining high standards, has shown a willingness to explore more agile regulatory approaches, particularly for rapidly evolving AI technologies. The MHRA published its strategic approach to AI in May 2024 and is set to publish a dedicated regulatory framework for AI as a medical device in 2026. This framework, informed by recommendations from the National AI Commission launched in September 2025, will introduce structured requirements for AI lifecycle governance, transparency, and cybersecurity, and will include continuous monitoring of AI-based medical devices. The MHRA’s draft Medical Devices (Amendment) Regulations 2026 also formalize Predetermined Change Control Plans (PCCPs) for AI and software devices, reflecting a move towards adaptive oversight. These approaches manifest in differences regarding the classification of certain AI functions, the acceptable scope of pre-market clinical validation, or the mechanisms for managing algorithmic drift in SaMD products, which the EU AI Act also directly addresses. These subtle differences, when observed across a range of AI health tools, reveal the practical implications of differing regulatory philosophies.

Tracing the International Thread: Tempus AI, HeartFlow, and Butterfly Network

Examining how specific AI health companies interact with these international regulatory signals provides concrete examples of the overlap and divergence. Tempus AI, operating in the complex space of precision medicine and oncology, has continued its engagement with various regulatory bodies for its AI-driven diagnostic and prognostic tools. Demonstrating this, Tempus has received multiple FDA 510(k) clearances for its ECG-AI products, including Tempus ECG-AF in July 2024, Tempus ECG-Low EF in July 2025, Tempus ECG-PH in August 2026, and Tempus ECG-MR in September 2026. Also, Tempus received 510(k) clearance for its RNA-based Tempus xR IVD device in September 2025. Its approach to data governance and the validation of its AI models for therapeutic guidance reflects principles that resonate across both the MHRA and EU MDR, particularly concerning the need for high-quality, representative datasets. Similarly, HeartFlow, with its AI-powered non-invasive coronary artery disease assessment, has navigated regulatory pathways that demand rigorous clinical validation and a clear demonstration of clinical utility. HeartFlow received FDA 510(k) clearance for its Next Gen HeartFlow Plaque Analysis algorithm in September 2025, which features improved plaque detection. Plus, Cigna announced in October 2025 that it would cover HeartFlow Plaque Analysis, becoming the second national insurer to do so, indicating progress in addressing reimbursement and adoption challenges. The extensive evidence required for its FFRct technology and plaque analysis tools shows the shared international emphasis on strong clinical data, regardless of the specific regulatory body. Butterfly Network, with its portable ultrasound devices enhanced by AI for image acquisition and interpretation, also offers a case study. In March 2026, Butterfly Network received FDA clearance for its fully automated Gestational Age (GA) Tool, integrated into its handheld ultrasound platform, marking the first approved AI-powered blind-sweep ultrasound solution for estimating gestational age. The classification of its AI features, whether as clinical decision support or as diagnostic tools requiring full SaMD scrutiny, has implications for its regulatory burden in both the UK and the EU. The MHRA’s evolving approach to AI in imaging, for example, might offer slightly different nuances in terms of required clinical validation or post-market surveillance protocols compared to the more centralized EU MDR interpretation. These companies, each a significant player in its respective domain, illustrate how the foundational requirements for safety and efficacy are largely consistent, even as procedural details may vary. EU MDR official text

What Divergence Reveals for Policy Analysts

The instructive read for policy analysts following these developments is not simply to note where frameworks differ, but to understand why they differ and what those differences imply for future regulation. A divergence in how the MHRA and EU MDR approach, for instance, the continuous learning capabilities of an AI model under a Predetermined Change Control Plan (PCCP) can signal different appetites for risk or different interpretations of what constitutes a “significant change” requiring re-submission. The FDA published final guidance on PCCPs in December 2024, and the MHRA is formalizing them in its 2026 draft regulations, indicating a growing international consensus on managing iterative AI changes. The MHRA might lean towards a more iterative, adaptive oversight model, whereas EU MDR, now with the added layer of the AI Act, might favor more rigid pre-market assessments. This gap in the record is precisely where the useful insights lie. It highlights areas where regulatory science is still evolving, where consensus is yet to fully form, and where future international harmonization efforts might focus. By understanding these nuances, policy analysts can better anticipate the trajectory of AI medical device regulation, identify potential bottlenecks for innovation, and advise on strategies for companies seeking to navigate multiple jurisdictions. The MHRA, in its distinct yet interconnected role, thus is more than just a national regulator. It is a valuable indicator of the broader currents shaping the global governance of AI in healthcare. Health Affairs article on AI regulation

Frequently Asked Questions

Why is the UK MHRA a valuable regulator to observe for international AI health investment trends?

The MHRA offers crucial insights because it provides a distinct voice in global AI medical device oversight and frequently engages with and influences international standards. Its positions can act as a bellwether for broader international trends, reflecting a pragmatic approach to innovation balanced with patient safety that many other regulators also seek. Observing the MHRA can illuminate areas of convergence and divergence with larger frameworks like the EU MDR.

How does the MHRA’s approach to AI medical device regulation compare to the EU MDR and EU AI Act?

Both the MHRA and EU frameworks emphasize robust clinical evidence, quality management systems, and post-market surveillance, with core tenets of Good Machine Learning Practice finding resonance in both. However, the EU MDR and EU AI Act present a highly prescriptive pathway with stringent conformity assessment and classify most AI-enabled medical products as ‘high-risk’. The MHRA, while maintaining high standards, explores more agile regulatory approaches, such as Predetermined Change Control Plans for AI, and is set to publish a dedicated framework in 2026.

What specific aspects of AI medical device regulation do the MHRA and EU frameworks address similarly or differently?

Both frameworks share principles like the need for high-quality, representative datasets, as seen in Tempus AI’s approach to data governance and model validation. They also both emphasize rigorous clinical validation and demonstration of clinical utility, as exemplified by HeartFlow’s FFRct technology. Divergences can occur in the specifics of implementation and interpretation, such as the classification of certain AI functions, the acceptable scope of pre-market clinical validation, or mechanisms for managing algorithmic drift.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.